Adrenal gland neuroblastoma

Summary

Adrenal gland neuroblastoma (MONDO:0006076) is a disease. A subtype of retroperitoneal neuroblastoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	adrenal gland neuroblastoma
Mondo ID	MONDO:0006076
EFO	EFO:1000075
DOID	DOID:5718
NCIT	C4827
SNOMED CT	281562007
UMLS	C0559460
MedGen	154328
GARD	0024283
Anatomy (UBERON)	UBERON:0002369
Is cancer (heuristic)	no

Also known as: adrenal gland neuroblastoma · adrenal neuroblastoma · neuroblastoma of adrenal · neuroblastoma of adrenal gland · neuroblastoma of the adrenal · neuroblastoma of the adrenal gland

Data availability: 56 cell lines.

Disease family

This is a subtype of retroperitoneal neuroblastoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › embryonal neoplasm › primitive neuroectodermal tumor › neuroblastic tumor › neuroblastoma › retroperitoneal neuroblastoma › adrenal gland neuroblastoma

Subtypes (1): adrenal gland ganglioneuroblastoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.